Loading organizations...

§ Private Profile · Raleigh, NC, USA
Biopharma company developing needle-free intranasal epinephrine products for life-threatening allergic reactions such as anaphylaxis.
Belhaven Biopharma is a Raleigh, North Carolina-based pharmaceutical company that develops needle-free dry powder nasal drug delivery solutions for emergency medical care and manufactures clinical trial materials. The organization focuses on advancing Nasdepi, an intranasal epinephrine product designed to treat life-threatening allergic reactions like anaphylaxis without auto-injectors. In October 2025, the enterprise received authorization from the FDA to begin biocomparability studies against intramuscular epinephrine. The business has financed its research and regulatory milestones through multiple capital raises, including a $3 million bridge round in 2023 and an oversubscribed Series A financing targeting $10 million in August 2025. The firm is backed by the North Carolina Biotechnology Center and features leadership associated with acquired pharmaceutical entities such as Oriel Therapeutics and Cirrus Pharmaceuticals. Belhaven Biopharma was founded in 2021 by Scott Lyman and Dave Neal.
Belhaven Biopharma has raised $10.0M across 1 funding round.
Belhaven Biopharma has raised $10.0M in total across 1 funding round.
Belhaven Biopharma has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 19, 2025 | $10M Series A | — | — | Announced |